Skip to main content
Publications
Rebordosa C , Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D , Garcia-Esteban R , Plana E , Tormos A , Farsani SF, Perez-Gutthann S , Pladevall-Vila M . Liver, renal, genitourinary, and diabetic ketoacidosis risks among new users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes: post-authorisation safety study based on multinational cohorts . Diabetes Obes Metab. 2024 Apr;26(4):1291-304. doi: 10.1111/dom.15429
Anthony L, Horsch D, Ervin C , Kulke MH, Pavel M, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz DC, Pasieka J, Pavlakis N, DiBenedetti D , Haydysch E, Yang QM, Jackson S, Arnold K, Law L, Lapuerta P. Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: patient exit interviews . Poster presented at the 2016 UKI NETS 14th National Conference; December 2016. London, UK. [abstract] Pancreas. 2016 Dec; 45(3):470. Previously presented at the 8th Symposium of the North American Neuroendocrine Tumor Society. doi: 10.1530/endoabs.46.P11
Herman WH, Hoerger TJ, Hicks K , Brandle M, Sorensen SW, Zhang P, Engelgau MM, Hamman RF, Marrero DG, Ackermann DT, Ratner RE. Managing people at high risk for diabetes . Ann Intern Med. 2006 Jan 3;144(1):66-7.